PTC Therapeutics, Inc. Receivables, Net, Current
PTC Therapeutics, Inc. (PTCT) had Receivables, Net, Current of $239.04 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-07-30
- 2026-06-30: Receivables, Net, Current $239.04M.
- 2026-03-31: Receivables, Net, Current $219.92M.
- 2025-12-31: Receivables, Net, Current $181.62M.
- 2025-09-30: Receivables, Net, Current $203.07M.
| Period end | Receivables, Net, Current |
|---|---|
| 2026-06-30 | $239.04M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $219.92M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $181.62M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $203.07M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $196.13M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $210.50M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $158.55M 10-K · filed 2026-02-19 |
| 2024-09-30 | $199.98M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $187.15M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $197.66M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $160.82M 10-K · filed 2025-02-27 |
| 2023-09-30 | $165.72M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $177.50M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $201.87M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $155.61M 10-K · filed 2024-02-29 |
| 2022-09-30 | $124.46M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $135.94M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $141.29M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $110.45M 10-K · filed 2023-02-21 |
| 2021-09-30 | $96.64M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $78.80M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $94.12M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $69.93M 10-K · filed 2022-02-22 |
| 2020-09-30 | $56.79M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $53.64M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $52.62M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $55.54M 10-K · filed 2021-02-25 |
| 2019-09-30 | $60.38M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $77.10M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $46.35M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $67.91M 10-K · filed 2020-03-02 |
| 2018-09-30 | $42.20M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $59.38M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $45.61M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $40.39M 10-K · filed 2019-03-01 |
| 2017-09-30 | $38.74M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $33.77M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $32.17M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $24.93M 10-K · filed 2018-03-06 |
| 2016-09-30 | $27.41M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $19.77M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $22.62M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $11.09M 10-K · filed 2017-03-16 |
| 2015-09-30 | $8.02M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $5.11M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $3.18M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $4.45M 10-K · filed 2016-02-29 |
| 2013-12-31 | $958.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |